论文部分内容阅读
目的:探讨中药制剂艾迪对骨肉瘤化疗的增效作用及其相关机制。方法:将艾迪与多柔比星单独及联合应用于骨肉瘤OS732细胞,MTT法检测细胞生长抑制率,流式细胞仪定量分析凋亡细胞所占比例,倒置相差显微镜及荧光显微镜下观察凋亡细胞形态改变,免疫细胞化学技术分析凋亡相关蛋白Fas表达。结果:艾迪与多柔比星对骨肉瘤细胞都有剂量依赖性杀伤作用,艾迪浓度达到25μL/mL时,细胞生长受到抑制,再增加艾迪浓度抑制率不再明显改变,但如与1μg/mL多柔比星合用将使细胞生长抑制率进一步提升,P=0.003。细胞超微结构观察及凋亡率测定结果也显示,艾迪与多柔比星联用可诱导更多骨肉瘤细胞凋亡,且联用时骨肉瘤Fas表达明显提升,P=0.005。结论:艾迪与小剂量多柔比星合用与单用多柔比星相比可更高效杀伤骨肉瘤细胞,此作用与上调Fas表达诱导骨肉瘤细胞凋亡有关。
Objective: To investigate the synergistic effect of Chinese traditional medicine Eddie on chemotherapy of osteosarcoma and its related mechanism. Methods: Adriamycin and doxorubicin alone and in combination were applied to osteosarcoma OS732 cells. MTT assay was used to detect the rate of cell growth inhibition. Flow cytometry was used to quantitatively analyze the percentage of apoptotic cells. Phase contrast microscopy and fluorescence microscopy were used to observe apoptosis The morphology of apoptotic cells was analyzed by immunocytochemistry. Results: Aidi and doxorubicin had a dose-dependent killing effect on osteosarcoma cells. When AID concentration reached 25 μL / mL, the cell growth was inhibited and then the inhibitory rate of Aidi no longer changed obviously. However, 1μg / mL doxorubicin combination will further increase the rate of cell growth inhibition, P = 0.003. Ultrastructural observation and apoptosis assay also showed that combination of ADE and doxorubicin could induce more apoptosis of osteosarcoma cells, and the expression of Fas in osteosarcoma was significantly increased when combined with P = 0.005. CONCLUSION: Aidi combined with low dose doxorubicin can kill osteosarcoma cells more efficiently than doxorubicin alone, which may be related to the up-regulation of Fas expression to induce osteosarcoma cell apoptosis.